6.30

11.52% -0.82

After Hours: 6.33 0.03 +0.48%

CorMedix Inc (CRMD)

Overview News Price History Option Chain Discussions Forecast Stock Split

CorMedix Inc stock is traded at $6.30, with a volume of 4.21M. It is down -11.52% in the last 24 hours and down -14.29% over the past month. CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Previous Close:

$7.12

Open:

$6.35

24h Volume:

4.21M

Relative Volume:

1.52

Market Cap:

$496.37M

Revenue:

$214.30M

Net Income/Loss:

$162.50M

P/E Ratio:

3.0685

EPS:

2.0531

Net Cash Flow:

$74.42M

1W Performance:

-14.29%

1M Performance:

-14.29%

6M Performance:

-49.19%

1Y Performance:

-37.69%

1-Day Range:

$6.1301

$6.55

1-Week Range:

$6.1301

$7.265

52-Week Range:

$5.60

$17.43

CorMedix Inc Stock (CRMD) Company Profile

Name

CorMedix Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

908-517-9500

Address

400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ

Employee

Twitter

Next Earnings Date

2025-03-25

Latest SEC Filings

CRMD's Discussions on Twitter

Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRMD CorMedix Inc	6.30	560.98M	214.30M	162.50M	74.42M	2.0531
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

CorMedix Inc Stock (CRMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Jun-30-25	Initiated	H.C. Wainwright	Buy
Mar-07-25	Initiated	Leerink Partners	Outperform
Jan-13-25	Initiated	D. Boral Capital	Buy
Aug-26-24	Initiated	Rodman & Renshaw	Buy
Aug-10-23	Initiated	RBC Capital Mkts	Outperform
Feb-17-21	Initiated	Needham	Buy
Sep-29-20	Initiated	JMP Securities	Mkt Outperform
Sep-21-20	Initiated	Truist	Buy
Dec-18-19	Initiated	B. Riley FBR	Buy
Mar-26-19	Reiterated	H.C. Wainwright	Buy
Dec-06-18	Initiated	ROTH Capital	Buy
Sep-25-17	Reiterated	H.C. Wainwright	Buy
Aug-10-17	Reiterated	Rodman & Renshaw	Buy
May-05-17	Reiterated	Rodman & Renshaw	Buy
Nov-11-16	Reiterated	FBR & Co.	Outperform
Mar-17-16	Reiterated	FBR Capital	Outperform
Mar-03-16	Initiated	FBR Capital	Outperform
Nov-16-15	Reiterated	ROTH Capital	Neutral
Oct-29-15	Reiterated	ROTH Capital	Neutral
May-06-15	Downgrade	ROTH Capital	Buy → Neutral
Dec-08-14	Reiterated	ROTH Capital	Buy
Oct-03-11	Downgrade	Maxim Group	Buy → Hold

View All

CorMedix Inc Stock (CRMD) Latest News

06:47 AM

Earnings call transcript: CorMedix Q4 2025 results miss EPS, stock dips - Investing.com India

09:48 AM

08:50 AM

CorMedix (CRMD) Lags Q4 Earnings Estimates - Yahoo Finance

08:50 AM

08:31 AM

CorMedix Q4 2025 Earnings Call Transcript - MarketBeat

08:31 AM

08:24 AM

Cormedix Earnings Review: Q4 Summary - Benzinga

08:24 AM

08:17 AM

CorMedix earnings missed by $0.69, revenue topped estimates - Investing.com

08:17 AM

08:15 AM

CorMedix: Q4 Earnings Snapshot - KVUE

08:15 AM

08:03 AM

CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com

08:03 AM

07:55 AM

CORMEDIX ($CRMD) Releases Q4 2025 Earnings - Quiver Quantitative

07:55 AM

07:53 AM

CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com India

07:53 AM

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView

07:53 AM

07:38 AM

CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance By Investing.com - Investing.com UK

07:38 AM

07:36 AM

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times

07:36 AM

06:15 AM

Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis

06:15 AM

Mar 04, 2026

Cormedix Earnings Preview - Benzinga

Mar 04, 2026

CRMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

Mar 02, 2026

Earnings Preview: CorMedix to Report Financial Results Pre-market on March 05 - 富途牛牛

Mar 02, 2026

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - marketscreener.com

Mar 02, 2026

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 - GlobeNewswire

Mar 02, 2026

Responsive Playbooks and the CRMD Inflection - Stock Traders Daily

Mar 02, 2026

CRMD Earnings History & Surprises | EPS & Revenue Results | CORMEDIX INC (NASDAQ:CRMD) - ChartMill

Mar 02, 2026

Mar 01, 2026

Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline? - Yahoo Finance

Mar 01, 2026

Feb 28, 2026

CRMD SEC FilingsCormedix 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 28, 2026

CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention - Sahm

Feb 28, 2026

Feb 27, 2026